Articles from Neurogastrx

Neurogastrx Announces NG101 Phase 2 Clinical Study Demonstrating Significant Reductions in Nausea and Vomiting Induced by GLP-1 Receptor Agonist Semaglutide

Results, presented at ObesityWeek® 2025, showed patients receiving NG101 saw 40% reduction in nausea incidence and 67% reduction in vomiting incidence

By Neurogastrx · Via GlobeNewswire · November 7, 2025

Neurogastrx to Present Proof-of-Concept Clinical Data on Oral Candidate NG101 to Reduce Nausea & Vomiting Associated with GLP-1 Agonists at ObesityWeek®

Nausea and Vomiting Are the Most Frequent Reasons for Discontinuing GLP-1 Therapies, Significantly Impacting Adherence, Titration and Preventing Achievement of Proven Long-Term Benefits

By Neurogastrx · Via GlobeNewswire · October 7, 2025

Neurogastrx Announces Positive Proof-of-Concept Data for Investigational Drug NG101 in Reducing Nausea and Vomiting Associated with the Administration of GLP-1 Agonist Medication

NG101 Significantly Reduced Incidence of Nausea by 40% and Frequency of Vomiting by 56% without Changing the Safety Profile of the GLP-1 Agonist

By Neurogastrx · Via GlobeNewswire · October 16, 2024